Preventing secondary brain injury after neurological insults is one of the primary goals of the neurocritical care unit. Our understanding of the roles of intracranial pressure (ICP) and cerebral edema in managing patients in the neurocritical care units is still evolving. Recent clinical trials examining the monitoring and treatment of elevated ICP have influenced the way we think about intracranial hypertension. Additionally, new methods of monitoring ICP, new physiologic surrogates derived from ICP measurements, and evolving technology to measure cerebral edema are currently being studied and tested for clinical efficacy. In this article, we will discuss both traditional and novel methods of monitoring ICP and cerebral edema.
INTRODUCTION
Recent studies investigating the clinical utility of intracranial pressure (ICP) monitoring, 1, 2 hemicraniectomy for the treatment of elevated ICPs 3, 4 and hypothermia for elevated coined by Harvey Cushing, states with an intact skull, the sum of the volume of brain, blood and CSF is constant: an increase in one causing a decrease in one or both of the remaining two. 6 The doctrine describes our ability to measure pressure to extrapolate changes in volume representing cerebral edema or other space occupying lesions. When the cerebral perfusion concept was introduced, there was a shift in focus from cerebral volume to pressure. 7 A normal ICP does not equate to a normal brain. Physiologic changes often precede increases in ICP. In addition, while a normal brain might exhibit very little ICP variations in its different compartments, a diseased brain will often exhibit compartmentalization of ICP between the two hemispheres across the falx cerebri and across the tentorium cerebri between the infra-and supra-tentorial compartments. This seems to precede a more generalized ICP increase as injury progresses and is important when considering the type and optimal placement of ICP monitoring devices. [8] [9] [10] [11] [12] In this review, we will stress the importance of ICP as a surrogate marker of increased intracranial volume. We will discuss the monitoring of ICP, non-invasive methods of ICP monitoring and novel methods of brain edema monitoring.
The results of the BEST-TRIP trial showing no difference in outcomes between a treatment protocol based on ICP monitoring versus that based on imaging and clinical examination has forced a re-examination of ICP thresholds. 2 The Brain Trauma Foundation previously promoted treatment of ICP a threshold of above 20 mmHg. 13 with low correlation between the amplitude and pressure (RAP<0.5) was described as a predictor of unfavorable outcome. 30 Baseline ICP measurement errors due to spontaneous drifts or shifts will effect RAP values accuracy. 
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Another telemetric device is the OSAKA telesensor (OSAKA telesensor; Nagano Keiki Seisakusyo Co. Ltd., Tokyo, Japan)
which is an ICP sensor embedded in a vericular shunt for patients with hydrocephalus showed accurate ICP measurement, diagnosed shunt malfunction correctly and was calibratable for zero drift by comparing the ICP reading from the telesensor with the puncture pressure in the onoff valve. 48 The use of these devices has not been investigated in the critical care setting.
NON-INVASIVE METHODS OF ICP MONITORING
The advantage of non-invasive methods is the relative safety, low cost and easy access. However, at the present time, non-invasive methods seem to have a common theme when effective: they may be able to confirm presence or absence of intracranial hypertension at best but they are unable to produce a surrogate numerical value that compares to the invasive methods of measuring ICP.
As ICU management becomes more individualized these methods may provide further insight into the individual cerebral autoregulatory status in lieu of a pure numerical interpretation ICP values.
Tympanic membrane displacement (TMD) measures the displacement on the tympanic membrane in response to the stapedial or middle ear reflex. 49 Significant differences in the TM displacement have been found between patients with raised and normal ICP. 50 TMD is mostly studied in children, it shows some benefit in monitoring a single patient longitudinally as an outpatient, decreasing the need for invasive ICP measurement in shunted patients with hydrocephalus. However, at this point TCD remains a poor surrogate for ICP because the inter subject variability is high and the predictive value of the technique is low.
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Another limitation is the that TMD measurement requires an intact tympanic membrane and perilymphatic duct which may limit its use in trauma patients. 32 As the use of ultrasound as a bedside technique in the critical care setting increases, measurements of optic nerve sheath diameter (ONSD) are more commonly used as a surrogate marker of elevated ICP. The optic nerve is surrounded by meningeal layers. The subarachnoid space surrounding the optic nerve is in continuation with that surrounding the brain. Thus, an increase in ICP may result in the expansion of the perineural optic nerve subarachnoid space which may be measured clinically as an increase in optic nerve sheath diameter (ONSD). 53 ONSD can be measured using computed tomography (CT ), MRI or ultrasound. 54, 55 In a study of 59 patients, ONSD of >5 mm on ocular ultrasound was shown to have 100% sensitivity and 83% specificity in detecting cranial CT findings of shift, edema, or effacement. 56 In a study of 62 patients, the largest ONSD ISEs can convert the concentration of a specific ion into an electrical potential that can be measured as an output signal. 79 This technique has been studied in rodents. Itshowed a significant controlled cortical injury-induced decrease in Na+ and increase in K+ as well as faster recovery in these concentrations with Vasopressin-1a receptor (V1aR) inhibition. 81 These electrodes are largely used in animal research and have limitations including their size, their use of fragile glass capillary tubes that are time-consuming to prepare, and their inability to measure at more than one depth.
Recent miniaturization and improvements of the design shows promise for potential use in clinical practice. 
NON-INVASIVE REAL TIME MONITORING
Cerebral electrical impedance (CEI) uses the same principle of electrical impedance to measure the brain water content and cerebral edema. The patient's head is shaved and two electrodes are placed frontally and mid-occipitally.
A constant current is applied to the patient's brain and impedence is recorded. 84 Multiple small studies have shown that an increase in hemispheric electrical impedance corresponds to an increase cerebral edema with ischemic stroke and perihematomal edema with ICH. [84] [85] [86] [87] Non-invasive Near Infrared Spectroscopy (NIRS) has been investigated to monitor cerebral blood flow and cerebral blood oxygenation intraoperatively and in the critical care setting. [88] [89] [90] Because a near infrared light scattering signal (NIRSS) is directly proportional to brain water content, NIRSS may be used to detect small amounts of brain swelling. NIRSS has been shown in animal models to measure increases in brain swelling, but was insensitive to changes in cerebral blood flow, blood oxygenation, or blood flowrelated changes in ICP. An increase in NIRSS was detectable prior to increases in ICP when caused by edema. 83, 91 While this method is yet to be validated extensively in humans, it was used in a small cohort as surrogate for increased cerebral edema in mountain sickness and patients with symptoms of acute mountain sickness (AMS) showed higher NIRSS values. 92 This study demonstrates the feasibility of using NIRSS to monitor changes in cerebral edema but more robust studies are needed to validate NIRSS as a surrogate for cerebral edema in humans.
BLOOD TESTS
A serum marker for cerebral edema or brain injury has been sought for decades. Similar to the "troponin of the brain" a serum marker would be non-invasive and could be monitored serially. Several markers have been proposed as markers of cerebral edema.
Endothelin-1 (ET-1) is a potent vasoconstrictor implicated in the pathogenesis of multiple brain injuries. It is implicated in increased BBB permeability leading to increased cerebral edema and infarct size in ischemic stroke. 93 The blockade of ET-1 in multiple ischemic stroke models has been shown to decrease secondary brain injury. 94, 95 Increased peri-hematomal ET-1 levels have been associated with increased BBB and worsening peri-hematomal edema in intracranial hemorrhage models. 96 Increased expression of ET-1 has been shown in traumatic brain injury (TBI) models and is associated with increased vasospasm and ischemia. 97 All this makes ET-1 a potential target for predicting the severity of secondary brain injury and developing therapeutic agents. ET-1 has been shown to predict the development of severe brain edema in ischemic stroke patient post Tpa. 98 ET-1 has also been shown to be a predictor of vasospasm in TBI patients ET. [99] [100] [101] [102] Current studies are limited by small sample sizes and more robust studies are needed to characterize the role of ET-1 levels in cerebral pathology. ET-1 may become a useful tool for predicting which patients may be at a higher risk to develop cerebral edema.
Matrix metalloproteinase-9 (MMP-9) is a proteolytic enzyme involved in remodeling the basal lamina and extracellular matrix. 103 Increased MMP-9 expression has been detected in ischemic stroke and has been associated with higher NIHSS, larger infarct sizes and risk for hemorrhagic transformation. [104] [105] [106] Cellular-fibronectin (c-Fn), a component of the basal lamina, has been shown to be more sensitive than MMP-9 in in the prediction of the edema development and malignant MCA syndrome. 107 Further studies are needed to characterize the utility of MMP-9 and c-Fn in the evaluation of cerebral edema and secondary brain injury.
CONCLUSION
Our understanding of the value of monitoring cerebral hemodynamics has been challenged by multiple recent studies. It is important to remember that monitoring ICP or edema by itself would never effect therapeutic outcomes;therapeutic trials evaluate the effectiveness of specific therapies in reducing morbidity rather than the effectiveness of the diagnostic modality used. That said, the value of the various monitoring methods discussed lies in the potential to improve our understanding of cerebral hemodynamics and physiology. Non-invasive techniques will allow us to monitor a broader population of patients and thus add to the overall understanding of cerebral edema.
As technology advances, our ability to monitor cerebral hemodynamics and cerebral edema will continue to improve.
Failure of clinical trials using monitoring devices are not failure of the devices but rather failures of the treatments used to treat the underlying pathophysiology. Without effective treatments for cerebral edema which tackle the underlying pathophysiology, monitoring devices, no matter how accurately they measure and record, will not translate into clinical benefit. Attention needs to focus on novel methods of treating ICP elevation and brain edema.
